NU-9: a drug aimed at stopping harmful protein clumps in Alzheimer’s and related dementias
Investigations of the protein aggregation inhibitor NU-9 and its derivatives: mode of action and impact on Alzheimer’s disease and related dementias
Researchers are developing the drug NU-9 and related compounds to stop toxic protein clumps and protect brain cells in people with Alzheimer’s disease and related dementias.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11195124 on NIH RePORTER |
What this research studies
This project develops NU-9 and similar compounds to block harmful protein aggregation that contributes to neuron damage in Alzheimer’s and related dementias. Scientists will study how these compounds work inside neurons using cell and animal models, examining effects on protein clumps, mitochondrial and endoplasmic reticulum health, and neuronal structure. Early lab results showed NU-9 improved the health of diseased neurons with different toxic proteins, so researchers will refine derivatives and map their modes of action. The aim is to move these laboratory findings toward therapies that could one day be tested in people with dementia.
Who could benefit from this research
Good fit: People living with Alzheimer’s disease or related dementias, especially those in earlier stages, would be the most relevant candidates for therapies developed from this work.
Not a fit: Patients whose symptoms arise from non–protein-aggregation causes or who are in very advanced stages of disease may be less likely to benefit.
Why it matters
Potential benefit: If successful, NU-9 could slow or prevent brain-cell damage and cognitive decline by blocking protein aggregation across several dementias.
How similar studies have performed: Preclinical laboratory work showed NU-9 reduces protein aggregation and improves neuron health, but it has not yet been tested in clinical trials.
Where this research is happening
Chicago, United States
- Northwestern University — Chicago, United States (Active)
Researchers
- Principal investigator: Ozdinler, Pembe Hande — Northwestern University
- Study coordinator: Ozdinler, Pembe Hande
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.